Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01518335 · ClinicalTrials.gov registry record · NA
Use of Platelet Rich Plasma Therapy for Acute Ankle Sprains in the Emergency Department
A NA study, sponsored by Albert Einstein Healthcare Network.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT01518335: Completed NA study, sponsored by Albert Einstein Healthcare Network.
NCT01518335 is a NA study that has completed, run by Albert Einstein Healthcare Network. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01518335, a NA study, has completed, sponsored by Albert Einstein Healthcare Network.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
This research study hopes to determine whether or not platelet rich plasma therapy improves healing time of moderate to severe ankle sprain in comparison to standard of care therapy.
Primary Outcome
The primary outcome of this investigation is change from baseline in LEFS score, a previous validated 80-point scale used to quantify lower extremity function. A difference of 9 points is considered clinically significant.
Interventions
- PROCEDURE Platelet rich plasma injection
- PROCEDURE Placebo Comparator: Placebo/Standard of Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-02 |
| Phase | NA |
What the finished NCT01518335 record still lists
NCT01518335 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Platelet rich plasma injection is the first listed.
NCT01518335 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01518335 about?
NCT01518335 is a clinical study titled "Use of Platelet Rich Plasma Therapy for Acute Ankle Sprains in the Emergency Department". This research study hopes to determine whether or not platelet rich plasma therapy improves healing time of moderate to severe ankle sprain in comparison to standard of care therapy.
What is the current status of trial NCT01518335?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2009-06. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01518335?
The interventions under investigation include: Platelet rich plasma injection (PROCEDURE), Placebo Comparator: Placebo/Standard of Care (PROCEDURE).
Who is sponsoring clinical trial NCT01518335?
This trial is sponsored by Albert Einstein Healthcare Network, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01518335's enrollment target sits among peer trials
38 1538th of 2000 higher than 461 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia